Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-005246
Filing Date
2025-02-24
Accepted
2025-02-24 16:16:17
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13250
2 JOINT FILING AGREEMENT ex-99-02242025_090216.htm EX-99.1 4362
  Complete submission text file 0001415889-25-005246.txt   19469
Mailing Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122
Business Address 4370 LA JOLLA VILLAGE DRIVE SUITE 1050 SAN DIEGO CA 92122 (858) 225-7696
Aardvark Therapeutics, Inc. (Subject) CIK: 0001774857 (see all company filings)

EIN.: 821606367 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94897 | Film No.: 25657202
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital Global Life Sciences Fund IV, L.P. (Filed by) CIK: 0001834150 (see all company filings)

EIN.: 981568621 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G